Skip to main navigation Skip to search Skip to main content

Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

  • Ian E. Krop
  • , Opeyemi A. Jegede
  • , Juneko E. Grilley-Olson
  • , Josh D. Lauring
  • , Edith P. Mitchell
  • , James A. Zwiebel
  • , Robert J. Gray
  • , Victoria Wang
  • , Lisa M. McShane
  • , Larry V. Rubinstein
  • , David Patton
  • , P. Mickey Williams
  • , Stanley R. Hamilton
  • , Scott A. Kono
  • , James M. Ford
  • , Agustin A. Garcia
  • , Xingwei D. Sui
  • , Robert D. Siegel
  • , Brian M. Slomovitz
  • , Barbara A. Conley
    • Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty

Research output: Contribution to journal › Article › peer-review

28   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Phase II Study of Taselisib in PIK3CA Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCIMATCH ECOG-ACRIN Trial (EAY131) Subprotocol I'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry